Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy

根除逃逸变异肿瘤细胞以进行癌症免疫治疗

基本信息

批准号：
10557758
负责人：
Yong Lu
金额：
$ 39.39万
依托单位：
METHODIST HOSPITAL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-01 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10557758
关键词：
Adenosine Adoptive Cell Transfers Adoptive Transfer Antigens Antitumor Response B-Lymphocytes CD19 Antigens CD19 gene CD22 gene CD8-Positive T-Lymphocytes Cell Lineage Cells Clinical Research Clinical Trials Color Data Disease remission Down-Regulation Extracellular Space Foundations Future Human Immune Immune response Immunotherapy Inflammatory Interferons Knock-out Leukocytes Light Lymphoma MS4A1 gene Malignant Neoplasms Mediating Melanins Modeling Mus Mutation Myeloid Cells Pathway interactions Patients Production Purinoceptor Recurrence Relapse Resistance Role Site Solid Neoplasm Stress Surface T-Lymphocyte T-Lymphocyte Subsets Testing Toxic effect Translating Tumor Immunity Tumor Tissue Tyrosinase related protein-1 Variant Work anti-tumor immune response antitumor effect base cancer cell cancer immunotherapy cell injury chimeric antigen receptor T cells cost experience extracellular humanized mouse immunogenic in vivo innovation melanoma monocyte mouse model neoplastic cell novel pre-clinical prevent recruit response tumor

项目摘要

Project Summary Recently, we discovered that adoptive transfer of CD39KO tumor-specific (mixed CD4+ and CD8+) T cells, resulted in long-term survival of mice bearing large established tumors. Unexpectedly, we found that these T cells promoted killing of antigen-loss-variants (ALVs) in vivo and prevented tumor recurrence. Moreover, transfer of CD39KO, but not control KO, tumor-specific T cells eradicated large chimeric tumors that contained 10% of ALVs and resulted in long-term tumor-free survival and protection against rechallenge with ALV tumor cells. Based on these novel findings, we hypothesize that transfer of tumor-specific CD39KO T cells will eradicate large established tumors and prevent recurrence of ALV tumors, due to their ability to directly kill the tumor cells and induce anti-ALV responses. Aim 1 will determine the contribution of type I IFN production at the tumor site in preventing recurrence of ALV tumors. Aim 2 will determine the role of CD39KO T cells in the recruitment of inflammatory myeloid cells and the induction of type I IFN production for tumor clearance. Aim 3 will determine whether human tumor-specific CD39KO T cells are also endowed with these abilities to effectively eradicate human tumors in humanized mice. These innovative and mechanistic studies will shed light on the mechanisms underlying CD39KO T cell-mediated antitumor immunity and will thus establish a foundation for translating this discovery into more effective immunotherapies using tumor-specific T-cell subsets in human cancers.

项目摘要最近，我们发现CD39KO肿瘤特异性（混合CD4+和CD8+）T细胞的过继转移，导致具有大型肿瘤的小鼠长期存活。出乎意料的是，我们发现这些T 细胞促进体内杀死抗原损伤变异剂（ALV）并防止肿瘤复发。而且， CD39KO的转移，但不能控制KO，肿瘤特异性T细胞根除了包含的大嵌合肿瘤 10％的ALV，导致长期无肿瘤的生存率和防止ALV肿瘤的补给细胞。根据这些新发现的结果，我们假设肿瘤特异性CD39KO T细胞的转移将消除大型已建立的肿瘤并防止ALV肿瘤的复发，因为它们有能力直接杀死该肿瘤肿瘤细胞并诱导抗ALV反应。 AIM 1将确定I型IFN生产的贡献防止ALV肿瘤复发的肿瘤部位。 AIM 2将确定CD39KO T细胞在炎性髓样细胞的募集以及I型IFN产生肿瘤清除率的诱导。目标3 将确定人类肿瘤特异性CD39KO T细胞是否也具有这些能力有效地消除人源性小鼠的人类肿瘤。这些创新和机械研究将摆脱阐明CD39KO T细胞介导的抗肿瘤免疫的机制，因此将建立一个使用肿瘤特异性T细胞将该发现转化为更有效的免疫疗法的基础人类癌症中的子集。